{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:11:45Z","timestamp":1791173505006,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cancer susceptibility candidate 2 (CASC2) was found underexpressed in multiple types of human malignancies. However, the specific role of CASC2 in AML remains uncertain. The purpose of this study is to explore the expression of CASC2 in patients with AML and healthy donors and its prognostic significance in AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Total RNA was isolated from bone marrow samples or peripheral blood samples of 87 patients with AML and 26 healthy adult donors. The expression of long noncoding RNA CASC2 was detected by quantitative real-time polymerase chain reaction. The association between CASC2 expression and other clinicopathological factors as well as its prognosis significance were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The peripheral blood mononuclear cell (PBMC) expression level of CASC2 in AML was significantly lower than that in the healthy control cohort (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0048), and in the bone marrow samples, CASC2 was significantly upregulated in patients with AML after the achievement of CR (median value: 0.041, range: 0.015\u20130.064) compared with that at newly diagnosis (median value: 0.017, range: 0.008\u20130.041) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002). The expression of CASC2 had a significant relationship with complete remission (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.019). Survival data assessed by Kaplan\u2013Meier curves showed that patients with lower CASC2 expression had shorter overall survival and disease-free survival than patients with higher CASC2 expression. Finally, Cox proportional hazards analysis demonstrated that CASC2 was an independent prognostic indicator for both OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013) and DFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) of AML.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>LncRNA CASC2 may serve as a new molecular biomarker for the early diagnosis and of AML, and may be an independent prognostic factor affecting the survival of patients with AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_1365_20","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:04:49Z","timestamp":1739793889000},"page":"728-735","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Expression of the long noncoding RNA CASC2 in acute myeloid leukemia and its prognostic significance"],"prefix":"10.4103","volume":"61","author":[{"given":"Sida","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Hu","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"R1-20250217","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms20112721","article-title":"Acute myeloid leukemia mutations: Therapeutic implications","volume":"20","author":"Papayannidis","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R2-20250217","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"'Acute myeloid leukemia: A comprehensive review and 2016 update'","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"R3-20250217","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: New drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"key":"R4-20250217","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20250217","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.blre.2017.11.001","article-title":"When the good go bad: Mutant NPM1 in acute myeloid leukemia","volume":"32","author":"Kunchala","year":"2018","journal-title":"Blood Rev"},{"key":"R6-20250217","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/JLP.JLP_164_18","article-title":"Cytogenetics'impact on the prognosis of acute myeloid leukemia","volume":"11","author":"Gupta","year":"2019","journal-title":"J Lab Physicians"},{"key":"R7-20250217","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"R8-20250217","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: A center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-20250217","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12967-017-1281-x","article-title":"Molecular targeting in acute myeloid leukemia","volume":"15","author":"Lim","year":"2017","journal-title":"J Transl Med"},{"key":"R10-20250217","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2217\/pgs-2018-0202","article-title":"Genomic profiling and predicting treatment response in acute myeloid leukemia","volume":"20","author":"Isidori","year":"2019","journal-title":"Pharmacogenomics"},{"key":"R11-20250217","doi-asserted-by":"crossref","first-page":"e25607","DOI":"10.7554\/eLife.25607","article-title":"lncRNA requirements for mouse acute myeloid leukemia and normal differentiation","volume":"6","author":"Delas","year":"2017","journal-title":"Elife"},{"key":"R12-20250217","doi-asserted-by":"crossref","first-page":"18679","DOI":"10.1073\/pnas.1422050112","article-title":"Expression and prognostic impact of lncRNAs in acute myeloid leukemia","volume":"111","author":"Garzon","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20250217","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3324\/haematol.2017.171645","article-title":"Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients","volume":"102","author":"De","year":"2017","journal-title":"Haematologica"},{"key":"R14-20250217","first-page":"3980","article-title":"Long noncoding RNA PVT1 as a novel serum biomarker for detection of cervical cancer","volume":"20","author":"Yang","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R15-20250217","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cam4.848","article-title":"AFAP1-AS1 is upregulated and promotes esophageal squamous cell carcinoma cell proliferation and inhibits cell apoptosis","volume":"5","author":"Luo","year":"2016","journal-title":"Cancer Med"},{"key":"R16-20250217","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/1471-2407-14-693","article-title":"Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells","volume":"14","author":"Zeng","year":"2014","journal-title":"BMC Cancer"},{"key":"R17-20250217","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3892\/or.2017.5802","article-title":"Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia","volume":"38","author":"Huang","year":"2017","journal-title":"Oncol Rep"},{"key":"R18-20250217","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.febslet.2015.04.061","article-title":"Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia","volume":"589","author":"Xing","year":"2015","journal-title":"FEBS Lett"},{"key":"R19-20250217","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/CBM-181198","article-title":"LncRNA CASC2 expression is down- regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway","volume":"23","author":"Zhou","year":"2018","journal-title":"Cancer Biomark"},{"key":"R20-20250217","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.biopha.2018.09.181","article-title":"Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a","volume":"108","author":"Li","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R21-20250217","first-page":"235","article-title":"CASC2a gene is down-regulated in endometrial cancer","volume":"27","author":"Baldinu","year":"2007","journal-title":"Anticancer Res"},{"key":"R22-20250217","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12935-019-0728-y","article-title":"Long non-coding RNA CASC2 upregulates PTEN to suppress pancreatic carcinoma cell metastasis by downregulating miR-21","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R23-20250217","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.abb.2018.01.013","article-title":"Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel","volume":"665","author":"Gao","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"R24-20250217","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ajh.23834","article-title":"Acute myeloid leukemia: 2014 update on risk-stratification and management","volume":"89","author":"Estey","year":"2014","journal-title":"Am J Hematol"},{"key":"R25-20250217","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R26-20250217","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2007.06566.x","article-title":"Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: A concise review","volume":"137","author":"Baldus","year":"2007","journal-title":"Br J Haematol"},{"key":"R27-20250217","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1200\/JCO.2007.14.0418","article-title":"Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study","volume":"26","author":"Neubauer","year":"2008","journal-title":"J Clin Oncol"},{"key":"R28-20250217","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/humu.20015","article-title":"Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer","volume":"23","author":"Baldinu","year":"2004","journal-title":"Hum Mutat"},{"key":"R29-20250217","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2017.01.003","article-title":"Long non-coding RNA CASC2 in human cancer","volume":"111","author":"Palmieri","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R30-20250217","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cellsig.2014.11.011","article-title":"Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21","volume":"27","author":"Wang","year":"2015","journal-title":"Cell Signal"},{"key":"R31-20250217","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41419-018-0350-2","article-title":"CASC2\/miR-24\/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8\/caspase-3","volume":"9","author":"Jin","year":"2018","journal-title":"Cell Death Dis"},{"key":"R32-20250217","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.abb.2017.05.001","article-title":"Modulation of CASC2\/miR-21\/PTEN pathway sensitizes cervical cancer to cisplatin","volume":"623","author":"Feng","year":"2017","journal-title":"Arch Biochem Biophys"},{"key":"R33-20250217","first-page":"2081","article-title":"Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p\/SYVN1 pathway","volume":"53","author":"Gao","year":"2018","journal-title":"Int J Oncol"},{"key":"R34-20250217","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3727\/096504018X15178740729367","article-title":"Upregulated lncRNA CASC2 May inhibit malignant melanoma development through regulating miR-18a-5p\/RUNX1","volume":"27","author":"Zhang","year":"2019","journal-title":"Oncol Res"},{"key":"R35-20250217","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.biopha.2017.10.146","article-title":"Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression","volume":"97","author":"Jiang","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R36-20250217","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00418-019-01794-4","article-title":"Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p\/CDK19","volume":"152","author":"Zheng","year":"2019","journal-title":"Histochem Cell Biol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1365_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:27:05Z","timestamp":1787837225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_1365_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_1365_20","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2021-01-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}